Business
Theralase(R) Investor Conference Call Reminder
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demo...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Investor Conference Call ReminderTheralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete ResponseToronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company's ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin (\"BCG\")-Unresponsive Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\") (\"Study II\"), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025.Participants are encouraged to submit questions in advance to [email protected] to ensure sufficient time for discussion.Zoom Meeting Link: https://us02web.zoom.us/j/81044841120 Webinar ID: 810 4484 1120Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by ZoomAn archived version will be available on the website following the conference call.Study II Update:As of November 7, 2025:88 patients have been treated with the primary Study Procedure, representing 97.8% of the targeted enrollment of 90 patients72 patients have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response16 patients remain pending study completionInterim Clinical Results Demonstrate:64.3% (54/84) of patients achieved a Complete Response (\"CR\") at any point in time.72.6% (61/84) achieved a Total Response (TR = CR + Indeterminate Response (\"IR\")).At the 450-day assessment,40% (18/45) of patients maintained a CR42.2% (19/45) maintained a TR, demonstrating durability of response.Theralase® remains on track to complete enrollment in 4Q2025, with data lock and regulatory submissions expected in 1Q2027.Financial Update:Theralase® has released its unaudited, condensed, consolidated, interim 3Q2025 financial statements for the period ended September 30, 2025.Financial Highlights - Nine Months Ended September 30,...